2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Victoria Furer, Tel Aviv Sourasky Medical Center, Tel Aviv University
  • ,
  • Christien Rondaan, University of Groningen
  • ,
  • Marloes W. Heijstek, Utrecht University
  • ,
  • Nancy Agmon-Levin, Tel Aviv University, Sheba Medical Center at Tel Hashomer
  • ,
  • Sander Van Assen, Treant Care Group
  • ,
  • Marc Bijl, Martini Ziekenhuis
  • ,
  • Ferry C. Breedveld, Leiden University
  • ,
  • Raffaele D'amelio, University of Rome La Sapienza
  • ,
  • Maxime Dougados, Universite Paris 5
  • ,
  • Meliha Crnkic Kapetanovic, Lund University
  • ,
  • Jacob M. Van Laar, Utrecht University
  • ,
  • A. De Thurah
  • Robert B.M. Landewé, University of Amsterdam, Rheumatology
  • ,
  • Anna Molto, Universite Paris 5
  • ,
  • Ulf Müller-Ladner, Giessen University
  • ,
  • Karen Schreiber, Guy's and St Thomas' NHS Foundation Trust, King Christian X's Hospital for Rheumatology Diseases
  • ,
  • Leo Smolar, Patient Research Partner
  • ,
  • Jim Walker, Patient Research Partner
  • ,
  • Klaus Warnatz, University of Freiburg
  • ,
  • Nico M. Wulffraat, Utrecht University
  • ,
  • Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv University

To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind79
Nummer1
Sider (fra-til)39-52
Antal sider14
ISSN0003-4967
DOI
StatusUdgivet - 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 190956472